v3.26.3
Note 13 - Segment Reporting and Geographic Information
9 Months Ended
Sep. 30, 2026
Notes to Financial Statements  
Segment Reporting [Text Block]

13.

Segment reporting and geographic information

 

The Company previously had two reportable segments, Plinabulin pipeline and TPD platform. The TPD platform segment was comprised of SEED’s operations, which have been presented as discontinued operations since December 2024 and therefore were not included in the segment information previously disclosed. Following the deconsolidation of SEED on September 30, 2026 (see Note 3), the Company operates as a single reportable segment, Plinabulin pipeline. The BVI Disposal Group, which comprised the Company’s Plinabulin operations in China, was also deconsolidated on September 30, 2026 and is presented as discontinued operations. Accordingly, prior-period information for the Plinabulin pipeline segment has been recast to exclude the results of the BVI Disposal Group.

 

The Company presents segment information after elimination of inter-company transactions. In general, revenues and operating expenses are directly attributable, or are allocated, to each segment. The Company allocates operating expenses that are not directly attributable to a specific segment, such as those that support infrastructure across different segments, to different segments mainly on the basis of usage, headcount, depending on the nature of the relevant operating expenses.

 

The Company’s Chief Executive Officer, as the CODM, uses segment net loss to allocate resources for each segment and to assess the performance of each segment, primarily by monitoring actual results versus approved budgets. Significant segment expenses are presented in the table below. Other segment items include interest income, other income, net, and income tax expenses. The CODM does not evaluate the performance of segments using asset or liability information.

 

   

Three months ended September 30,

   

Nine months ended September 30,

 
   

2025

   

2026

   

2025

   

2026

 
     

$

     

$

     

$

     

$

 
   

(unaudited)

   

(unaudited)

   

(unaudited)

   

(unaudited)

 

Clinical and pre-clinical expenses

    428       676       720       1,742  

Patent expenses

    169       92       644       302  

Personnel costs

    562       512       2,148       1,662  

Professional services

    233       569       1,587       1,398  

Other operational expenses

    248       214       756       641  

Other segment items

    (18 )     1       (69 )     (9 )

Segment net loss

    1,622       2,064       5,786       5,736  

Reconciliation of net loss (income):

                               

Net loss (income) from discontinued operations

    3,322       (52,556 )     2,637       (43,854 )

Net loss (income)

    4,944       (50,492 )     8,423       (38,118 )

 

The Company’s long-lived assets of continuing operations by geographic area are presented as follows:

 

   

As of

 
   

December 31, 2025

   

September 30, 2026

 
     

$

     

$

 

 

         

(unaudited)

 
Property and equipment, net:              
                 

U.S.

    155       117  
                 

Total

    155       117